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Metabolic coupling of intracellular pathogens with
host cells is essential for successful colonization of
the host. Establishment of intracellular infection by
the protozoan Trypanosoma cruzi leads to the devel-
opment of human Chagas’ disease, yet the functional
contributions of the host cell toward the infection
process remain poorly characterized. Here, a
genome-scale functional screen identified intercon-
nected metabolic networks centered around host
energy production, nucleotide metabolism, pteridine
biosynthesis, and fatty acid oxidation as key pro-
cesses that fuel intracellular T. cruzi growth. Addi-
tionally, the host kinase Akt, which plays essential
roles in various cellular processes, was critical for
parasite replication. Targeted perturbations in these
host metabolic pathways or Akt-dependent signal-
ing pathways modulated the parasite’s replicative
capacity, highlighting the adaptability of this intracel-
lular pathogen to changing conditions in the host.
These findings identify key cellular process regu-
lating intracellular T. cruzi growth and illuminate the
potential to leverage host pathways to limit T. cruzi
infection.
INTRODUCTION
Chagas’ disease is a progressive and debilitating parasitic
disease that develops over decades in a subset of individuals
chronically infected with the obligate intracellular protozoan
Trypanosoma cruzi. Current global estimates indicate that 8–11
million people are infected with T. cruzi, primarily in rural Latin
America, and of these, roughly 3 million will develop life-threat-
ening, incurable chronic Chagasic syndromes (World Health
Organization, 2012). Parasite persistence in cardiac and smooth
muscle, with accompanying inflammation and immune dysregu-
lation, plays an essential role in the pathogenesis of Chagas’
disease (Gutierrez et al., 2009; Tarleton, 2001), where links to
host metabolic perturbations are emerging (Garg et al., 2004;
Machado et al., 2011). T. cruzi infection impacts cardiac energy
metabolism (Garg et al., 2004) in which attenuated mitochondrial108 Cell Host & Microbe 13, 108–117, January 16, 2013 ª2013 Elsevfunction in the heart is associated with the development and
progression of Chagasic cardiomyopathy (Wen et al., 2004).
Moreover, persistent T. cruzi infection of adipose tissue in
chronic Chagas’ patients (Ferreira et al., 2011) predicts long-
term consequences of the associated inflammation on host
glucose and lipid metabolism, which may influence disease
progression. As the currently available drugs to treat Chagas’
disease exhibit toxicity and fail to clear intracellular parasites in
the chronic stage of infection, the need to develop treatments
for this neglected disease is paramount.
The vertebrate stages of T. cruzi consist of nondividing ‘‘trypo-
mastigote’’ forms that actively penetrate a wide variety of host
cell types to establish intracellular infection and ‘‘amastigote’’
forms that proliferate in the host cell cytoplasm. The current
model of the T. cruzi trypomastigote invasion process was
derived from the collective contribution of several laboratories
over the past two decades (reviewed in Caradonna and Burleigh,
2011). In contrast to these efforts, the cellular and metabolic
processes required to fuel the growth of intracellular T. cruzi
amastigotes remain largely unknown (Gutteridge and Gaborak,
1979; Inbar et al., 2012; Robello et al., 1997; Ullman and Carter,
1997). Thus, a global determination of the components, function,
and consequence of host cellular pathways that are exploited by
intracellular T. cruzi growth and survival will have significant
implications for the understanding and treatment of chronic Cha-
gas’ disease.
Toward this end, we have performed a genome-wide RNA
interference (RNAi) screen targeting genes in mammalian host
cells to identify cellular processes that support intracellular
T. cruzi infection. Host factors associated with T. cruzi infection
identified in a recent study (Genovesio et al., 2011) did not
identify the primary points of action. A critical element of our
screening strategy is the inclusion of secondary screens de-
signed to discriminate host functional pathways that impact
trypomastigote invasion and the prereplication phase (<24 hr
postinfection) from host processes that support intracellular
T. cruzi amastigote growth (>24–90 hr). Consistent with the
current view of the T. cruzi invasion process, we find that estab-
lishment of intracellular residence by this pathogen is largely
influenced by host cell signaling molecules and cytoskeletal
proteins. In contrast, the intracellular replicative phase of the
T. cruzi infection cycle is supported by host metabolic networks
and cellular signaling pathways, a subset of which were vali-
dated with small molecule inhibitors and biochemical rescue
experiments. Thus, the ability to modulate the intracellularier Inc.
Figure 1. Genome-wide siRNA Screen Differentiates Host Processes Important for Trypanosoma cruzi Invasion and Growth
(A) Overall strategy for the three-phase RNAi screen.
(B) Schematic for set up of T. cruzi growth assay and primary and secondary screen readouts. Note that secondary screens exploited both the multiplexed plate
assay and an image-based readout in parallel with endpoints of 18 hpi and 72 hpi, to discriminate effects of host gene knockdown on intracellular parasite growth
from prereplication events in the parasite life cycle (illustrated in circular inset).
(C) Ranked MAD z scores of relative infection data from primary screen.
(D) Functional breakdown of secondary screen hits that impact intracellular parasite infection (18 hr) and growth (72 hr) from Table S2, manually curated from
UniProt.
See also Figure S1, Table S1, and Table S2.
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T. cruzi Growth Is Coupled to Host Metabolismreplicative capacity T. cruzi amastigotes by targeting host
cellular and metabolic pathways offers an experimental tool
that can be exploited to probe the intimate connections forged
between T. cruzi and its mammalian host cell.
RESULTS
A Genome-wide RNAi Screen in Mammalian Host Cells
Identifies Interconnected Metabolic Pathways as Key
Regulators of Intracellular T. cruzi Growth
To gain functional insights into host cellular pathways exploited
by T. cruzi during the establishment andmaintenance of intracel-
lular infection, we established a three-phase RNAi screen in
mammalian cells (Figure 1A). In the primary screening phase,
an arrayed human small interfering RNA (siRNA) library consist-
ing of 25,586 siRNA pools (four individual siRNAs/pool) was
assayed in HeLa cells to determine the impact of host cell
gene silencing on T. cruzi infection with a multiplexed end-point
parasite growth assay (Figure 1B and Figure S1 available online).
This assay permitted the simultaneous measurement of b-galac-
tosidase-expressing T. cruzi (Beta-Glo) and host cell abundance
(Cell Titer-Fluor) as detailed in the Experimental Procedures. For
each well, the median absolute deviation (MAD) for the BetaGlo/
Cell Titer-Fluor ratios was derived and used as the first criterion
for assigning hits: a MAD z score of %1.75 or R2.5. Wells in
which host cell abundance was %40% of nontargeting siRNA
controls were excluded. Based on these criteria, the primaryCell Hostscreen yielded 359 siRNA pools (1.69% of total) that restrict
T. cruzi infection and 293 siRNA pools (1.38%) that enhance
intracellular parasite burden (Figure 1C and Table S1). Focusing
primarily on siRNA pools that caused an overall reduction in the
intracellular burden of T. cruzi, we rescreened 240 selected
pools in the parasite growth assay (Figure 1B) as four individual
siRNAs deconvoluted from the original pool. We find that 81% of
the siRNA pools contained at least one siRNA that reproduced
the original effect on parasite infection (Table S1). At the rescre-
ening stage, a few additional siRNAs that did not make the signif-
icance cutoffs in the primary screen, but which represented
‘‘borderline’’ hits or genes involved in emerging pathways of
interest, were included. Genes with unknown function were not
considered for further testing. Efficient gene silencing in HeLa
cells was observed for the siRNA pools tested (Figure S2A).
To discriminate host factors that influence early steps in the
establishment of intracellular T. cruzi infection (invasion, vacuole
biogenesis, and cytosolic localization) from factors regulating
intracellular growth of cytosolic T. cruzi amastigotes, we con-
ducted secondary screens to measure relative parasite infection
levels at pre- and postreplication time points (18 and 72 hours
postinfection [hpi], respectively) (Figures 1B and S2B). In accor-
dance with their distinct roles in the parasite life cycle, host
genes associated with T. cruzi invasion and intracellular replica-
tion (Table S2) displayed discrete patterns of functional enrich-
ment (Figure 1D). Our results reveal that the prereplication phase
of the T. cruzi infection cycle is predominantly affected by host& Microbe 13, 108–117, January 16, 2013 ª2013 Elsevier Inc. 109
Figure 2. Schematic of InterconnectedHost
Metabolic Pathways that Influence Intracel-
lular Growth of T. cruzi Amastigotes
Highlighted are host genes that, when silenced
with specific siRNA pools, reduce (yellow) or
enhance (blue) intracellular growth of T. cruzi
amastigotes. Underlining indicates pathways for
known T. cruzi auxotrophies. See also Figure S2.
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T. cruzi Growth Is Coupled to Host Metabolismcell signaling pathways and cytoskeletal regulators (Table S2), in
line with our current understanding of the parasite invasion
process (Caradonna and Burleigh, 2011). In contrast, host
factors associatedwith T. cruzi amastigote growth inmammalian
cells were highly enriched for metabolic functions (Figure 1D and
Table S2). Despite functional leads to the parasite internalization
process, we concentrated on host pathways that impact the
intracellular growth of T. cruzi amastigotes, for which little is
currently known. Within this group, we focused on the subset
with the highest enrichment and most promising pharmacolog-
ical targets, specifically Akt signaling and hits related to glucose,
lipid, nucleotide, and energy metabolism (Figure 2).
Perturbations in Host Glucose and Fatty Acid
Metabolism Alter Intracellular Parasite Growth Rates
In mammalian hosts, T. cruzi replicates and persists within
tissues that exhibit high rates of fatty acid metabolism (Fritz,
1961), such as cardiac muscle, smooth muscle, and adipose
(Brener, 1973; Combs et al., 2005; Macedo and Pena, 1998;
Ferreira et al., 2011). The rate of fatty acid oxidation in the mito-
chondria is controlled by the flux of glucose through the glyco-
lytic pathway and the rate of conversion of pyruvate to acetyl
CoA by pyruvate dehydrogenase (PDH). T. cruzi infection of
cardiac tissue triggers early upregulation of host fatty acid
b oxidation genes followed by downregulation of the PDH
complex (Garg et al., 2004). As a negative regulator of PDH,
pyruvate dehyrogenase kinase 4 (PDK4) functions as the main
gatekeeper of the balance between glucose and fatty acid oxida-
tion (Sugden et al., 2001). Here, we find that T. cruzi growth is
poorly supported in PDK4-depleted cells (Figure 3A) that display
increased PDH activity (Figure 3B) and decreased fatty acid
oxidation (Figure 3C). Consistent with the idea that increased
flux of pyruvate through PDH contributes to a cellular environ-
ment that is restrictive for T. cruzi amastigote growth, we find110 Cell Host & Microbe 13, 108–117, January 16, 2013 ª2013 Elsevier Inc.that intracellular replication of T. cruzi is
enhanced in primary human fibroblasts
that exhibit reduced PDH activity (80%
reduction) (data not shown; Constanto-
poulos et al., 1986) (Figure 3D). Predicted
consequences of decreased PDK4 levels
and increased PDH activity include a
decrease in cellular pyruvate pools and
a shift in the fuel utilization balance from
fatty acid oxidation toward glucose
oxidation (Figure 3E) (Sugden et al.,
2001). As pyruvate supplementation of
the growth medium fails to rescue
T. cruzi growth in PDK4-depleted cells
(data not shown), the interaction of intra-cellular T. cruzi amastigotes with host pyruvate metabolism
may be more complex than the fulfillment of a nutritional
requirement. (Note that pyruvate uptake by T. cruzi has not
been demonstrated.) Instead, T. cruzi amastigotes may display
a growth advantage under conditions where host cell fatty acid
oxidation is favored over glucose utilization.
In mammals, b oxidation occurs in the peroxisomes and
the mitochondria (Poulos, 1995). Very-long-chain fatty acids
(VLCFAs;RC22) are transported into peroxisomes and oxidized
to produce shorter-chain fatty acids that are shuttled to themito-
chondria for continued oxidation by a number of acyl-CoA dehy-
drogenases (ACADs) to ultimately produce acetyl CoA (Ghisla
and Thorpe, 2004). Consistent with the notion that T. cruzi amas-
tigotes flourish in an environment that favors fatty acid oxidation,
peroxisomal proteins involved in activation/transport of VLCFAs
(SLC27A2) and b oxidation (ACAA1 and IDH1) were identified in
our screen as positively associated with intracellular T. cruzi
growth (Figure 2). In addition, primary human fibroblasts defi-
cient in mitochondrial ACADVL (Fang et al., 2000), which accom-
modates substrate acyl chains of (RC16), sustain significantly
lower levels of intracellular T. cruzi growth (Figure 3D). In
contrast, parasite growth restriction was not observed in cells
deficient for medium- or short-chain ACADs (data not shown).
Combined, these data identify long-chain fatty acid oxidation
as a key process in mammalian host cells associated with intra-
cellular T. cruzi growth. The upregulation of fatty acid utilization
pathways in axenically derived T. cruzi amastigotes (Atwood
et al., 2005) indicates the likelihood that fatty acid metabolism
in the intracellular parasite is coupled with that of their mamma-
lian hosts. Whether T. cruzi amastigotes avail of fatty acid
intermediates generated in host peroxisomal or mitochondrial
oxidative pathways or whether they benefit indirectly from the
production of energy and reductive intermediates formed in
these catabolic processes remains to be determined.
Figure 3. Intracellular T. cruzi Growth Is
Coupled to Host Fatty Acid Metabolism
(A) Western blot of knockdown (inset) and distri-
bution data for the number of intracellular para-
sites in HeLa cells transfected with nontargeting
siRNA (siControl) or siPDK4 at 72 hpi. Bar graph
values were derived from image-based analysis of
secondary screening data (Table S2).
(B and C) PDH activity (B) and b oxidation (C)
measured in HeLa cells transfected with non-
targeting (siControl) or siPDK4 (n = 6). Error bars
indicate the standard error (**p < 0.01, ***p <
0.001).
(D) Primary human fibroblasts deficient in pyruvate
dehydrogenase (PDH) or acyl-CoA dehydroge-
nase (very-long chain) ACADVL were infected with
T. cruzi and counted 48 hpi. Scatter plots of
numbers of parasites/infected cell for 100 infected
cells (per cell line) with the median highlighted
(black line) are shown. Significance was deter-
mined by a Kruskal-Wallis test followed by Dunn’s
Multiple Comparison test to directly compare
infection of metabolically deficient cells to healthy
control (***p < 0.001). Experiment was repeated
three times with similar results.
(E) Schematic of balance between PDH regulation
and fatty acid oxidation and its effects on parasite
growth.
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T. cruzi Growth Is Coupled to Host MetabolismParasite Growth Is Dependent on the Availability of
Host-Derived Cofactors and Metabolic Products
Inmammalian cells, electrons generated via fatty acid boxidation
and amino acid catabolism in themitochondria are transferred to
Coenzyme Q10 (CoQ10) via the electron transfer flavoprotein
dehydrogenase ETFDH (Figure 2). Limitation of CoQ10 produc-
tion in host cells by silencing of the biosynthetic enzyme trans-
prenyltransferase (TPRT) restricts intracellular amastigote
growth (Figure 4A). The parasite growth defect is completely
restored with CoQ10 supplementation of the culture medium
(Figure 4B). In addition to its role inmitochondrial energy produc-
tion, CoQ10 is critical for de novo pyrimidine synthesis (Lo´pez-
Martı´n et al., 2007) and exhibits antioxidant properties (Jeya
et al., 2010). T. cruzi growth in TPRT knockdown cells is partially
restored with the addition of uridine but not after supplementa-
tion with the antioxidant N-acetylcysteine (NAC) (Figure 4B).
These data indicate that CoQ10 deficiency in the host restricts
T. cruzi growth by limiting the availability of pyrimidines. While
T. cruzi has pyrimidine synthetic capability (Gutteridge and Ga-
borak, 1979), our host functional data imply that intracellular
amastigotes are reliant on host pyrimidine pools to support their
growth. Consistent with this observation, limitation of pyrimidine
nucleoside and/or nucleobase generation downstream of the
host cytosolic nucleotidase, NT5C3, is suboptimal for intracel-
lular T. cruzi growth (Figure 2).
Purines and pteridine auxotrophy (Gutteridge and Gaborak,
1979; Robello et al., 1997) predicts that intracellular T. cruzi
amastigotes will scavenge these essential nutrients from the
host cell cytosol. As biochemical data for the amastigote forms
of T. cruzi are limited (Gutteridge and Gaborak, 1979; Nakajima-Cell HostShimada et al., 1996), the functional links to host purine and
pteridine metabolic pathways uncovered in our unbiased
RNAi screen were particularly valuable (Figure 2). Limitation of
tetrahydrobiopterin production in host cells by silencing of
a key biosynthetic enzyme GTP cyclohydrolase 1 (GCH1)
restricts intracellular T. cruzi growth (Figure 4C) where the
parasite growth defect is rescued after biochemical supplemen-
tation of GCH1-depleted cells with 7,8 dihydro-L-biopterin
(Figure 4D). These findings provide functional evidence that
intracellular T. cruzi amastigotes are tightly coupled to the bio-
pterin biosynthetic capabilities of the host cell. Purines are
acquired by trypanosomatids from the environment via mem-
bers of parasite-encoded equilibrative nucleoside transporters
(Landfear, 2008) (http://tritrypdb.org/tritrypdb/). Silencing of
purine nucleoside phosphorylase (PNP) in host cells has
the predicted consequence of limiting purine nucleoside to
nucleobase conversion. As such, the associated increase in
T. cruzi amastigote growth in PNP-depleted cells was striking
(Figure 2) and leads to the testable hypothesis that intracellular
stages of T. cruzi preferentially transport purine nucleosides.
Combined with functional evidence that host pyrimidines are
critical for fueling intracellular amastigote growth (Figure 4B),
despite the capacity for de novo synthesis (Gutteridge and
Gaborak, 1979), data from our RNAi screen provide functional
evidence for the reliance of T. cruzi amastigotes on host purine
and pyrimidine pools as suggested by inhibitor studies (Naka-
jima-Shimada et al., 1996). These findings may have important
implications considering purine and pyrimidine salvage path-
ways in intracellular T. cruzi amastigotes as potential thera-
peutic targets.& Microbe 13, 108–117, January 16, 2013 ª2013 Elsevier Inc. 111
Figure 4. Modulation of Perturbed Pathways with Metabolite
Supplementation Restores Parasite Growth
(A) Distribution data for the number of intracellular T. cruzi in HeLa cells
transfected with nontargeting siRNA (siControl) or siRNAs targeting trans-
prenyltransferase TPRT (siTPRT), which is required for CoQ10 synthesis.
(B) Scatter plots of intracellular parasites in infected cells transfected with
nontargeting control (siControl) or siTPRT supplemented with CoQ10 (5 mM),
uridine (10 mM), or N-acetylcysteine (NAC; 1 mM).
(C) Distribution data for the number of intracellular parasites in HeLa cells
transfected with nontargeting siRNA (siControl) or siRNAs targeting GTP
cyclohydrolase 1 (GCH1), the first enzyme in the biopterin synthesis pathway.
(D) Supplementation of growth medium with 7,8 dihydro-L-biopterin rescues
T. cruzi growth defect in GCH1-depleted cells.
(B and D) Black lines indicate the count median for each treatment. Sig-
nificance was determined between control unsupplemented TPRT- or
GCH1-deficient cells (blue) and other conditions (green) by a Kruskal-Wallis
test followed by Dunn’s Multiple comparison test (***p < 0.001). Scatter plot
distributions shown are representative of three independent experiments.
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T. cruzi Growth Is Coupled to Host MetabolismHomeostatic mechanisms that maintain high ATP/ADP ratios
are critical for cell viability and growth. As such, preservation
of cellular nucleotide pools is likely to present a fundamental
challenge for T. cruzi-infected host cells. The majority of cellular
ATP is generated in themitochondria in a reaction that is coupled
to oxidative phosphorylation and the transfer of electrons gener-
ated via glucose, fatty acid, and amino acid catabolism. Host
genes participating in these processes emerged in our
secondary screen as strongly associated with intracellular
T. cruzi amastigote growth (Figures 1D and 2 and Table S2),
including a catalytic subunit of the mitochondrial ATP synthase,
ATP5B. Limitation of the conversion of cytosolic ATP to other
nucleoside triphosphates via transphosphorylation reactions
catalyzed by nucleoside diphosphate kinases, such as NME3
and NME4, significantly boosts intracellular T. cruzi growth (Fig-
ure 2 and Table S1), suggesting that maintenance of cellular
ATP/ADP ratios provides a distinct advantage for the parasite112 Cell Host & Microbe 13, 108–117, January 16, 2013 ª2013 Elsevthat could include keeping the activity of AMPK in check (as
demonstrated in Figure 5H, acute silencing of AMPK catalytic
or regulatory subunits provides amore favorable growth environ-
ment for intracellular T. cruzi). Viewed within the larger context of
nucleotidemetabolism, these data highlight critical nodes in host
bioenergetic and nutrient-generating pathways to which cyto-
solically localized T. cruzi amastigotes couple to meet metabolic
needs.
Genetic and Pharmacological Targeting of Host Akt
Signaling Inhibits Intracellular T. cruzi Replication
The serine/threonine kinase, Akt, participates in an extensive
cellular network that controls multiple pathways, including pro-
survival responses, glucose metabolism, and nutrient sensing
via the mTORC1 pathway (Huang and Manning, 2009; Weich-
hart, 2012). Akt is activated in a variety of mammalian host cells
during the T. cruzi invasion process (Chuenkova et al., 2001;
Woolsey et al., 2003) prompting a prosurvival response in
infected host cells that is sustained throughout the intracellular
parasite growth cycle (Chuenkova and PereiraPerrin, 2009).
Here, our genome-wide RNAi screen has uncovered a role for
host Akt as a regulator of intracellular T. cruzi growth. Acute
silencing of AKT1 restricts intracellular T. cruzi growth in
HeLa cells without discernable effects on prereplication events
in the parasite life cycle (Figures 5A–5C). Whereas isoform
specificity for AKT1 was observed in HeLa cells, silencing of
both AKT1 and AKT2 in mouse embryonic fibroblasts (MEFs)
and human dermal fibroblasts (HFFs) was necessary to
observe comparable effects on T. cruzi growth (Figures S3A
and S3B). The availability of highly selective inhibitors of
AKT1/2 isoforms (Green et al., 2008) permits chemical valida-
tion of Akt signaling as a key host cell pathway regulating intra-
cellular T. cruzi replication. Pharmacological targeting of host
AKT1/2 with the allosteric inhibitor AktVIIIi restricts intracellular
parasite growth and signaling (Figures 5D and 5E) in a range of
mammalian cell types (Figure S3C), with the exception of AKT1/
2-deficient MEF in which residual T. cruzi growth is refractory to
AktVIIIi (Figure 5F). To determine whether targeting of host Akt
inhibits the replicative capacity of the parasite, we established
a proliferation assay for intracellular T. cruzi amastigotes based
on flow cytometric analysis of CFSE stained parasites (Fig-
ure 5G). In untreated cells, five generations of intracellular
T. cruzi amastigotes can be resolved by 48 hr postinfection.
Treatment of infected fibroblasts with AktVIIIi at 18 hpi (imme-
diately prior to the first division of intracellular parasites) re-
sulted in significant inhibition of parasite proliferation following
an initial round of parasite cell division (Figure 5G). Thus, phar-
macological targeting of host Akt demonstrates the proof-of-
principle concept that unbiased functional screens are valuable
tools for the identification of cellular targets in mammalian host
cells that, when inhibited pharmacologically, restrict intracel-
lular T. cruzi infection. This principle can be applied to any
druggable molecular target that emerges from this or similar
screening approaches.
T. cruziGrowth Is Enhanced byManipulation of Anabolic
Growth Pathways
The mammalian target of rapamycin (mTOR) complex 1
(mTORC1) is an Akt-dependent pathway that senses cellularier Inc.
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(Huang and Manning, 2009; Weichhart, 2012). mTORC1
signaling is inhibited by nutrient and growth factor deficiency
or by treatment with the small-molecule inhibitor rapamycin.
Perturbations in the host mTORC1 pathway in T. cruzi-infected
cells revealed in transcriptomic studies (Costales et al., 2009)
suggest that T. cruzi intersects this host pathway, directly or
indirectly. Consistent with this suggestion, acute silencing
of genes encoding catalytic (PRKAA1) and noncatalytic
(PRKAB1) subunits of AMP kinase (AMPK), a negative regulator
of mTORC1, significantly enhance intracellular growth of T. cruzi
(Figure 5H, Table S1, and Table S2). To better assess the impact
of mTORC1 on parasite replication, we exploited a HeLa cell line
stably expressing short hairpin RNA (shRNA) targeting tuberous
sclerosis protein 2 (TSC2), an Akt substrate and a negative regu-
lator of mTORC1 for infection studies. We find that T. cruzi
growth is insensitive to rapamycin in control cells; however,
constitutive activation of mTORC1 in shTSC2 cells (Huang
et al., 2008) fueled increased intracellular T. cruzi growth in a
rapamycin-sensitive manner (Figure 5I). The observation that
both basal andmTORC1-stimulated T. cruzi growth are sensitive
to AktVIIIi, whereas only the accelerated parasite growth in
TSC2-depleted cells is sensitive to rapamycin (Figure 5I),
exposes the plasticity of parasite populations with respect to
their ability to access mTORC1-dependent and independent
pathways downstream of Akt to support replication in mamma-
lian cells (Figure 5J). The ability of T. cruzi to integrate its meta-
bolic needs with different host cellular pathways would offer a
level of flexibility to facilitate parasite survival in the face of
changing environmental conditions encountered as the parasite
adapts to life in multiple hosts and cell types in nature.
DISCUSSION
At the outset of the present study, we had little prior knowledge
of host cellular pathways that function to support intracellular
infection by the obligate intracellular parasite, Trypanosoma
cruzi. As a result of the unbiased functional screen and accom-
panying experimental validation reported here, we are now
able to place the predicted metabolic dependencies of T. cruzi
(Gutteridge and Gaborak, 1979; Inbar et al., 2012; Ullman and
Carter, 1997) within a larger interconnected framework encom-
passing nucleotide metabolism, glucose/fatty acid metabolism,
host energetics, and Akt signaling. The identification of biochem-
ical pathways in our screen that yield products known to be
required for T. cruzi growth and replication (i.e., purine and
biopterin) provides a high level of confidence in the functional
associations that have emerged in the screen.
A functional link between host CoQ10 production, pyrimidine
biosynthesis, and T. cruzi amastigote growth was exposed in
our unbiased siRNA screen. Acute silencing of host TPRT, which
is required for CoQ10 biosynthesis, dramatically inhibited the
growth of intracellular amastigoteswithout exerting a detrimental
effect on the host cell. In biochemical supplementation experi-
ments, we were able to show that addition of CoQ10 was suffi-
cient to rescue parasite growth. The ability to restore parasite
growth with uridine supplementation as well suggests that the
main requirement for CoQ10 is associated with its activity as
a cofactor for the pyrimidine biosynthetic enzyme, dihydrooro-Cell Hosttate dehydrogenase. Considering that T. cruzi has the capacity
to synthesize pyrimidines de novo, the inferred reliance on host
pyrimidine pools was not expected. Collectively, these findings
highlight the utility of a functional genomics approach to identify
critical regulators of the dynamic T. cruzi-host interaction.
The emergence of the host serine/threonine kinase Akt as
a regulator of T. cruzi amastigote replication was unexpected,
considering the extensive focus on Akt as a key mediator of
the prosurvival response triggered by T. cruzi (Chuenkova and
PereiraPerrin, 2009). The coupling of T. cruzi amastigote replica-
tion to a critical regulator of host cell survival suggests a sophis-
ticated strategy for establishment of long-term infection in the
host. It should be noted that T. cruzi is not unique in its exploita-
tion of host Akt-signaling pathways (Kuijl et al., 2007; Kumar
et al., 2010), where its influence on host phagolysosomal fusion
events is manipulated by intracellular bacteria (Kuijl et al., 2007).
The mechanistic basis for the influence of host Akt on T. cruzi
replication remains to be determined. However, given its wide
functional reach in mammalian cells, including a prominent role
in glucose and lipid metabolism (Hay, 2011), the influence of
host Akt on intracellular T. cruzi replication is likely to be
multifactorial.
Several observations suggest that intracellular T. cruzi amas-
tigotes benefit from a host cell metabolic environment that favors
fatty acid oxidation over glucose oxidation. Acute silencing
of PDK4, the main gatekeeper of the balance between glucose
and fatty acid utilization, inhibits amastigote growth, whereas
parasites exhibit a growth advantage in cells with PDH defi-
ciency. Host genes involved in very-long-chain fatty acid
oxidation in host peroxisomes were identified in the screen as
influencing parasite growth, and cells with defective mitochon-
drial fatty acid oxidation were less competent to support intra-
cellular T. cruzi growth. Proteomic evidence shows that the
amastigote form of the T. cruzi life cycle upregulates the capacity
for fatty acid uptake and oxidization (Atwood et al., 2005), sug-
gesting the natural coupling of T. cruzi growth to fatty acid
metabolism in the host.
Alongside functional insights emerging from our study, our
observations suggest a level of plasticity in T. cruzi amastigotes
populations in which intracellular parasite growth rates are
responsive to environmental cues. While this is a highly intuitive
concept—i.e., restricting ‘‘nutrient’’ pools should slow intra-
cellular parasite growth—our study provides experimental
evidence that intracellular T. cruzi growth can be significantly
altered ([ or Y) simply by perturbing host cellular functions.
This flexibility is further exemplified by the differential ‘‘usage’’
of host Akt-dependent pathways, both mTORC1-dependent
and -independent, to fuel intracellular T. cruzi amastigote
growth, exposing layers of redundancy with respect to host
pathway utilization by the parasite. The capacity for adaptation
would be especially relevant in the context of a dynamic natural
infection in the mammalian host. Plasticity within parasite popu-
lations, reflected in an ability to alter growth rates to match
particular metabolic microenvironments, may be a critical mech-
anism underlying tissue tropism and persistent infection. Selec-
tive persistence of T. cruzi in muscle and adipose tissue presents
the possibility that cellular metabolism characteristic to these
tissues, such as an increased reliance on fatty acid metabolism
for energy production (Fritz, 1961), offers a selective advantage& Microbe 13, 108–117, January 16, 2013 ª2013 Elsevier Inc. 113
Figure 5. Host Cell Akt Regulates Intracellular T. cruzi Growth via mTORC1-Dependent and -Independent Mechanisms
(A) Western blot of AKT1 and AKT2 expression levels in HeLa cells as compared to b-actin, after siRNA-mediated silencing of AKT1, AKT2, and AKT3 isoforms
singly and in combination.
(B) Silencing of AKT1 in HeLa cells inhibits intracellular T. cruzi growth (72 hpi) but not the ability to establish intracellular infection (18 hpi) as determined
with the multiplexed plate assay (detailed in the Experimental Procedures) and compared to nontargeting control siRNA. Data are represented as the
mean ± SD (n R 3).
(C) Distribution plots of intracellular T. cruzi amastigotes (number of parasites/infected cell) in HeLa transfectedwith nontargeting control siRNA (siControl) or after
acute silencing of AKT1 (siAkt).
(D) Relative phospho-AktSer473 levels in HeLa cells determined by western blot in mock-infected, T. cruzi-infected, or insulin-stimulated (Ins) cells 72 hpi in 0.5%
serum-containing media. AktVIIIi was added to cells at 18 hpi.
(E) Dose-dependent inhibition of T. cruzi growth in HeLa cells treated with AktVIIIi at 18 hpi and relative infection measured at 72 hpi with the multiplexed plate
assay. Values represent the mean ± SD (nR 3).
(F) T. cruzi growth in AKT1/2 knockout MEFs measured at 72 hpi is significantly lower than in WT controls and refractory to 1 mM AktVIIIi added at 18 hpi.
(legend continued on next page)
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punishing immune response.
Despite suggestions of flexibility and adaptation to changing
environmental conditions, T. cruzi growth in mammalian cells is
highly susceptible to targeted perturbations in host metabolic
and signaling functions. As such, pharmacological targeting of
host metabolism to uncouple intracellular T. cruzi from its
nutritional dependencies may prove an effective strategy for
controlling pathogen spread. The concept of host-targeted
therapies is not new for virologists (Ikeda and Kato, 2007;
Schols, 2004) and is gaining traction for nonviral pathogens
(Jayaswal et al., 2010; Kuijl et al., 2007). Drug discovery efforts
for Chagas’ disease have focused primarily on the identification
of target pathways in the parasite (Buckner and Navabi, 2010).
However, with inherent heterogeneity in drug sensitivity among
T. cruzi isolates/strains (e.g., Bustamante and Tarleton, 2011),
the consideration of host-targeted therapies for Chagas’ disease
as an alternative to, or in combination with, antitrypanosomal
compounds is clearly warranted. This study opens an opportu-
nity in the Chagas’ disease field to exploit host genetics and
small molecules to gain fundamental insights into the T. cruzi
infection process with a view toward the identification of phar-
macological targets in the parasite and the host.
EXPERIMENTAL PROCEDURES
siRNA Screen
HeLa cells were reverse transfected with arrayed siRNA SMARTpools (50 nM)
(Thermo Fisher Scientific, Lafayette, CO) complexed in Oligofectamine
reagent (Invitrogen). At 48 hr posttransfection, cells were infected with
T. cruzi multiplicity of infection (MOI) 5 for 2 hr, followed by two washes with
PBS and incubation in Dulbecco’s modified Eagle’s medium (DMEM) contain-
ing 2% fetal calf serum (FCS), 100 units/ml penicillin, 100 mg/ml streptomycin,
10 mM HEPES, and 2 mM L-glutamine (D2) (phenol free) for a total of 72 hr.
Each assay plate also included ketoconazole (15 mM) as a positive control
for inhibition of T. cruzi growth, siRNA to polo-like kinase1 (PLK1) as a control
for transfection and cell death, and nontargeting siControl (Dharmacon
siRNA#2). The screen was performed in triplicate or duplicate according to
plate content, i.e., library plates enriched in pseudogenes or genes of unknown
function were screened in duplicate.
Multiplexed T. cruzi Infection Assay
Trypanosoma cruzi Tulahu´en strain stably expressing b-galactosidase (gener-
ously provided by Fred Buckner, University of Washington) was maintained by
weekly passage in LLcMK2 cells (ATCC) as described (Woolsey et al., 2003).
Relative intracellular T. cruzi-b-galactosidase infection and host cell viability
were measured in a multiplexed plate assay with CellTiterFluor (Cell Viability
Assay; Promega, Madison, WI) and Beta-Glo reagent (Promega), per the
manufacturers’ protocol, measured on the EnVision Plate Reader (Perkin
Elmer). The MAD for the ratio of BetaGlo/Cell Titer-Fluor (LUM/INTENS) values
measured in each well for each screening plate was calculated. The MAD(G) Intracellular CFSE-labeled T. cruzi amastigotes measured by flow cytometry
overlapping intensity to extracellular CFSE-labeled parasites fixed at time 0 (blu
panel). AktVIIIi (1 mM) added at 18 hpi inhibits T. cruzi proliferation (right panel).
(H) Acute silencing of PRKAB1, the regulatory subunit of AMPK, enhances intrac
(I) Constitutive mTORC1 activation in stable TSC2 knockdown HeLa cells (shTSC
expressing shRNA to firefly luciferase (shLUC) and is sensitive to rapamycin (500
(F and I) Lines indicate the parasite/cell median. Significance was determined by K
shown are representative of two to three independent observations.
(J) Proposed interaction of T. cruzi with Akt-activated mTORC1-dependent an
resulting in decreased intracellular T. cruzi growth (yellow) or increased growth (
See also Figure S3.
Cell Hostz score [z = (x – m) / (MAD * K)] was calculated for each SMARTpool on
the plate, where x is the LUM/INTENS for each well, m is the median LUM/
INTENS of the plate, MAD is the median absolute deviation of the LUM/
INTENS ratios on the plate, and K is the scale factor 1.4826. A SMARTpool
was further considered if the MAD z score was %1.75 or R2.5 and
R40% host cell viability (%v = [(x – background) / (plate ave – background)])
of each well, where x is the intensity value for the well, ‘‘background’’ is the
average PLK1 intensity for the plate, and ‘‘plate ave’’ is the average intensity
for the plate. In assays where the plate components were not pinned at
random, as in the cherry picked and secondary assays, the LUM/INTENS
was compared to the LUM/INTENS of control siRNA2. A SMARTpool
was considered a hit if the relative ratio [(LUM/INTENS)target siRNA / (LUM/
INTENS)control siRNA] scored %0.66 and fulfilled the R40% cell viability cutoff
established above.
Secondary Screens
For secondary screens, custom plates containing selected siRNA pools
(purchased from Dharmacon; Thermo Fisher Scientific, Lafayette, CO) target-
ing annotated genes in pathways that emerged as hits in the primary or rescre-
ening phases of the genome-wide screen. HeLa cells were transfected as
above, with the exception that 25 nM (final) siRNA was assayed per well
and each siRNA pool was assayed in three independent T. cruzi infection
experiment with at least two biological replicates per experiment. Mean
LUM/INTENS values were determined across experiments for each siRNA
SMARTpool that was considered a candidate ‘‘hit’’ if the relative ratio
scored %0.66 (comparing target to control siRNA, as above) and fulfilled
theR40%host cell viability cutoff at 18 or 72 hpi. In addition to themultiplexed
plate assay, a parallel group of plates was fixed in 4% paraformaldehyde/PBS
and DAPI stained, and image-based detection of intracellular parasites was
collected with the In Cell 2000 High Content Analyzer (GE Healthcare). For
the siRNA pools confirmed in the multiplexed plate readout as having a signif-
icant impact on intracellular T. cruzi growth, images were used to obtain data
for the relative number of intracellular parasites/infected cell with manual
confirmation. These distributions were compared to the nontargeting siRNA
control group with the Mann-Whitney test. In some instances, binned distribu-
tions were plotted for clarity.
Pyruvate Dehydrogenase Activity
HeLa cells were reverse transfectedwith 25 nM siRNA in a 6-well plate. At 24 hr
posttransfection, media was exchanged for D2 and at 48 hr was exchanged
again for D2 (without pyruvate and phenol indicator). At 72 hr posttransfection,
cells were washed with PBS, and lysates were collected in 80 ml provided
sample buffer containing Complete Mini-EDTA free protease inhibitor cocktail
(Roche) on ice. Protein concentration in clarified lysates (3,000 rpm spin for
10 min) was measured with the DC Protein Assay (BioRad) and adjusted to
the same concentration in 50 ml. Pyruvate dehydrogenase activity was
measured in each sample with a PDH activity assay kit (Abcam) according
to the manufacturer’s instructions. Assays were read on an Epson photo
quality scanner, and densitometry for each band was calculated with Alpha
View software version 3.1.1.0 (Alpha Innotech).
b Oxidation Assay
Transfected cells (as above) were loaded with 2 mCi 3H-palmitate (Perkin
Elmer) for 2 hr in media containing 2% fatty acid-free BSA, 0.25 mM carnitine,
and low glucose DMEM. Resulting 3H2O released from b oxidation into thereveal a uniform undivided population at 18 hpi (generation = 0, red line) with
e) (left panel) and five distinct generations at 48 hpi in untreated HFFs (middle
ellular growth of T. cruzi as confirmed in secondary screens.
2) enhances T. cruzi growth (measured at 48 hpi) as compared to control cells
nM) and AktVIIIi (2 mM) added at 18 hpi.
ruskal-Wallis and Dunn’sMulitple Comparison tests (***p < 0.001). Experiments
d -independent signaling pathways. siRNA-mediated depletion of host gene
blue) is shown.
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extractions with 10% TCA, 5% TCA/10% BSA, and chloroform:methanol.
Supernatant was collected, added to 5 ml Ecolume scintillation fluid (MP
Biomedicals), and radioactivity was measured. All activity measurements
were normalized to total protein quantified from cell lysates.
Biochemical Supplementation
HeLa cells (20,000) were reverse transfected, as indicated above, with 25 nM
control or TPRT- or GCH1-targeting siRNA (Dharmacon/Thermo Fisher
Scientific, Lafayette, CO) and seeded onto 10 mm round coverslips (Electron
Microscopy Sciences, Hatfield, PA). At 18 hr posttransfection, media was
exchanged for D2 supplemented with CoQ10 (Sigma-Aldrich, St. Louis, MO)
(solubilized in ethanol to 5 mM, diluted in FCS, then in serum-free DMEM to
final concentrations of 5 mM CoQ10 and 2% FCS), 10 mM Uridine (Sigma-
Aldrich), 1 mM N-acetylcysteine (NAC) (Sigma-Aldrich), 7,8 dihydro-L-
biopterin (Caymen Chemicals, Ann Arbor, MI), or vehicle controls. At 48 hr
posttransfection, cells were infected with T. cruzi (MOI = 5) for 2 hr, washed
twice to remove unattached parasites, and left in supplemented media. At
72 hr postinfection, cells were rinsed with sterile PBS and fixed in 2% parafor-
maldehyde/PBS. Parasite and host nuclei were DAPI stained, and parasites
per infected cell were counted by fluorescent microscopy with an Eclipse
TE300 (Nikon Instruments Inc., Melville, NY) under 603 magnification.
T. cruzi Growth Inhibition
Parasite-infected cells were treated at 18 hpi with AktVIIIi (EMD Chemicals,
Cambridge, MA) or rapamycin (Tocris, Minneapolis, MN), and relative infection
was determined in a multiplexed plate assay as described above. Intracellular
T. cruzi/infected cell was determined for a minimum of 100 cells after visual-
ization/counting of parasite and host cell nuclei with DAPI. The median
number of intracellular parasites was compared to the corresponding
untreated control with a Kruskal-Wallis test followed by Dunn’s Multiple
Comparison test.
T. cruzi Amastigote Proliferation Assay
Freshly isolated T. cruzi trypomastigotes were labeled with 1.5 mM CFSE from
the CellTrace CFSE Cell Proliferation Kit (Life Technologies) per the manufac-
turer’s protocol. Subconfluent monolayers of HFFs were infected with CFSE-
labeled parasites to achieve one parasite/infected cell for most infected
cells prior to the first parasite replication event. Monolayers were washed
extensively and cells harvested by scraping and five passages through a 26
gauge needle to liberate the intracellular amastigotes at both 18 hpi (prerepli-
cation) and 48 hpi (postreplication). Cellular debris was removed by centrifuga-
tion. Relative CFSE fluorescence was measured for 10,000 parasites by
LSRFortessa (BD Biosciences), and proliferation was plotted and analyzed
by FloJo Data Analysis Software (Tree Star, Inc.).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and two tables and can be found with this article online at
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